Meningioma: Novel Diagnostic and Therapeutic Approaches
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: 31 August 2025 | Viewed by 1296
Special Issue Editor
Interests: neurology; neuro-oncology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue, titled “Meningioma: Novel Diagnostic and Therapeutic Approaches”, will collate innovative research and comprehensive reviews focused on novel diagnostic and treatment modalities for meningiomas. In light of the accumulating evidence for molecular markers in the grading of meningiomas, PET DOTATATE for the detection of meningiomas, and targeted therapies for the treatment of meningiomas, this Special Issue will explore the advancements made in these areas.
We invite submissions that highlight novel imaging modalities, molecular alterations, and targeted therapies for meningiomas. Topics may include (but are not limited to) the application of PET DOTATATE for the identification of viable tumor and in radiation planning, molecular alterations that predict recurrence risk, and innovative therapies, including Lutetium-177 and targeted therapies. Contributions addressing challenges in identifying novel molecular markers to stratify risk are more than welcome. This Special Issue aims to provide a broad detailed overview of the recent advancements made and future directions in the diagnosis and treatment of meningiomas. This Special Issue will provide a guide for neuro-oncologists to support improved patient outcomes and deliver personalized medicine to their patients.
Dr. Carlen A Yuen
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- meningioma
- atypical
- anaplastic
- PET DOTATATE
- octreotide
- Lutetium-177
- targeted therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
